CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Toshinari Yamashita on Eribulin Plus Trastuzumab-Pertuzuma for Advanced HER2+ Breast Cancer – Alternative first-line regimen gets green light from EMERALD trial ...

Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC).

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

To date, Hengrui has advanced over 10 differentiated ADC candidates into clinical development, including Trastuzumab rezetecan, its flagship HER2 -targeted ADC therapy.

Patients with HER2-positive and HER2-low metastatic breast cancer who received concurrent trastuzumab deruxtecan and radiotherapy were identified. Data on patient demographics, treatment regimens, ...

Trastuzumab deruxtecan (T-DXd) monotherapy in advanced HER2-positive or HER2-low/ultralow breast cancer: An updated pooled analysis of prospective clinical trials.. If you have the appropriate ...

Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer over 10 years.

Herceptin is approved for the treatment of early stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive (HER2-positive) and has spread into the lymph nodes, or is HER2 ...

Herceptin is approved for the treatment of early stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive (HER2-positive) and has spread into the lymph nodes, or is HER2 ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.